Review Article
Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved Issues
Table 2
Outcome of haploidentical transplantation for children with acute leukemia without T cell depletion.
| | Ref. |
Number of patients with AL (total) |
Age range (years) | Disease status |
Conditioning | Graft composition | GVHD prophylaxis | Engraftment (%) | Acute GVHD (%) |
Chronic GVHD (%) |
NRM (%) |
Relapse (%) | Overall survival (%) | CD34
(×106) | CD3
(×107) |
| | Liu et al. (2013) [51] | 212 | 3–18 | NR = 24
CR = 188 | AraC/BU/CY
Semustin/ATG | 2.5 | 1.88 | Multiagent | 100% | 48.8% | 40.1% | <2008: 16.8%
>2008: 12.2% | <2008: 28.3%
>2008: 17.5% | <2008: 61.1%
>2008: 71.5% |
| | Sawada et al. (2014) [65] | 9 (15) | 2–17 | Ref./Rel.: 7
CR = 2 | FLU/MEL | NA | NA | PTCY based | 80% | 55.6% | NA | 28.5% | 57.1% | Ref./Rel.: 14.2%
CR = 100% |
| | Jaiswal et al. (2016) [66, 67] | 20 | 2–20 | AML
Rel./Ref.: 13
ALL CR: 7 | FLU/BU/MEL | 7.5 | 6.85 | PTCY based | 100% | 35% | 5% | 20% | 25.7% | 64.3% |
|
|
AL: acute leukemia; ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ATG: antithymocyte globulin; BU: Busulfan; CR: complete remission; CY: cyclophosphamide; GVHD: graft-versus-host disease; FLU: Fludarabine; MA: myeloablative conditioning; Mel.: Melphalan; NR: not in remission; NRM: nonrelapse mortality; Ref.: refractory; Rel.: relapsed; TBI: total body irradiation; TT: thiotepa.
|
